**Amendments to the Claims:**

1. (Currently amended) A method of ~~treatment of allergic asthma~~ treating late asthmatic response in a patient comprising administering to the patient a maintenance dose of an IgE antagonist and, optionally, a loading dose of the IgE antagonist wherein said IgE antagonist is (a) an antibody or antigen-binding fragment thereof, that prevents the binding of free IgE to FceRI, but does not bind to FceRI-bound IgE, (b) a soluble IgE receptor or (c) or an IgE binding peptide capable of disrupting or blocking the interaction between IgE and its receptors .

2. (Original) The method of claim 1, wherein the maintenance dose is repeated at intervals of about 1 to about 90 days.

3. (Original) The method of claim 2, wherein the maintenance dose is repeated weekly.

4. (Original) The method of claim 2, wherein the maintenance dose is repeated biweekly.

5. (Original) The method of claim 1, wherein the IgE antagonist is an anti-IgE antibody.

6. (Original) The method of claim 5, wherein the antibody is chimeric.

7. (Original) The method of claim 6, wherein the antibody is humanized.

8. (Original) The method of claim 5, wherein the antibody is a human antibody.

9. (Original) The method of claim 1, wherein the antagonist binds to soluble IgE and blocks the binding of IgE to the IgE receptor on basophils.

10. (Original) The method of claim 5, wherein the antibody binds to soluble IgE and blocks the binding of IgE to the IgE receptor on basophils.

11. (Original) The method of claim 1, wherein the loading dose is administered before onset of asthma symptoms.

12. (Original) The method of claim 1, wherein the loading dose is administered after the onset of asthma symptoms.

13. (Original) The method of claim 1, wherein the loading dose is greater than the maintenance dose.

14. (Original) The method of claim 1, wherein the antagonist is administered in a formulation comprising a buffer, a salt, optionally, a polyol, and optionally, a preservative.

15. (Original) The method of claim 14, wherein the antagonist is freeze-dried, then reconstituted before administration.

16. (Original) The method of claim 1, wherein the maintenance dose, and optionally, the loading dose reduce the concentration of free IgE in the patient's serum to less than about 40 ng/ml.

17. (Original) The method of claim 1, wherein the maintenance dose of antagonist is about 0.001 to 0.01 mg/kg/week/baseline IgE IU/ml.

18. (Original) The method of claim 1, wherein the maintenance dose, and optionally, the loading dose, results in a total serum concentration of antagonist of about 1 to 10 times greater than the patient's total serum IgE concentration.

19. (Currently amended) A method for treating ~~allergic asthma~~late asthmatic response in a patient comprising administering to the patient a dose of IgE antagonist averaging about 0.001 to 0.01 mg/kg/week IgE antagonist for every IU/ml baseline IgE in the patient's serum, wherein said IgE antagonist is (a) an antibody or antigen-binding fragment thereof, that prevents the binding of free IgE to FceRI, but does not bind to FceRI-bound IgE, (b) a soluble IgE receptor or (c) or an IgE binding peptide capable of disrupting or blocking the interaction between IgE and its receptors .

20-39. Canceled

40 (New). A method of treating allergic asthma comprising a maintenance dose of an anti-IgE antibody in combination with the administration of an adjuvant selected from the group consisting of antihistamine, theophylline, salbutamol, beclomethasone, diproprionate, sodium cromoglycate, a steroid and an anti-inflammatory agent.

41 (New). The method of Claim 40, wherein the adjuvant is administered before the anti-IgE antibody.

42 (New). The method of Claim 40, wherein the adjuvant is administered after the IgE antibody.

43 (New). The method of Claim 40, wherein the adjuvant is antihistamine.

44 (New). The method of Claim 40, wherein the adjuvant is theophylline.

45 (New). The method of Claim 40, wherein the adjuvant is salbutamol.

46 (New). The method of Claim 40, wherein the adjuvant is beclomethasone.

47 (New). The method of Claim 40, wherein the adjuvant is diproprionate.

48 (New). The method of Claim 40, wherein the adjuvant is sodium cromoglycate.

49 (New). The method of Claim 40, wherein the adjuvant is a steroid.

50 (New). The method of Claim 40, wherein the adjuvant is an anti-inflammatory agent.